Israel
· Delayed Price · Currency is ILS · Price in ILACBI Statistics
Total Valuation
Clal Biotechnology Industries has a market cap or net worth of ILS 62.90 million. The enterprise value is 99.30 million.
| Market Cap | 62.90M |
| Enterprise Value | 99.30M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Clal Biotechnology Industries has 156.85 million shares outstanding. The number of shares has increased by 24.92% in one year.
| Shares Outstanding | 156.85M |
| Shares Change (YoY) | +24.92% |
| Shares Change (QoQ) | -17.54% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 5.75% |
| Float | 55.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.06 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.33 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.18, with a Debt / Equity ratio of 0.28.
| Current Ratio | 2.18 |
| Quick Ratio | 2.18 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.16 |
Financial Efficiency
Return on equity (ROE) is -60.69% and return on invested capital (ROIC) is -3.42%.
| Return on Equity (ROE) | -60.69% |
| Return on Assets (ROA) | -3.36% |
| Return on Capital (ROIC) | -3.42% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.80% in the last 52 weeks. The beta is 0.69, so Clal Biotechnology Industries's price volatility has been lower than the market average.
| Beta (5Y) | 0.69 |
| 52-Week Price Change | -11.80% |
| 50-Day Moving Average | 39.91 |
| 200-Day Moving Average | 41.78 |
| Relative Strength Index (RSI) | 54.04 |
| Average Volume (20 Days) | 186,525 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Clal Biotechnology Industries had revenue of ILS 32,000 and -74.74 million in losses. Loss per share was -0.43.
| Revenue | 32,000 |
| Gross Profit | 32,000 |
| Operating Income | -8.13M |
| Pretax Income | -71.90M |
| Net Income | -74.74M |
| EBITDA | -8.06M |
| EBIT | -8.13M |
| Loss Per Share | -0.43 |
Balance Sheet
The company has 9.54 million in cash and 23.13 million in debt, giving a net cash position of -13.59 million or -0.09 per share.
| Cash & Cash Equivalents | 9.54M |
| Total Debt | 23.13M |
| Net Cash | -13.59M |
| Net Cash Per Share | -0.09 |
| Equity (Book Value) | 82.94M |
| Book Value Per Share | 0.38 |
| Working Capital | 5.56M |
Cash Flow
| Operating Cash Flow | -8.05M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -25,396.88% |
| Pretax Margin | -224,700.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Clal Biotechnology Industries does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.92% |
| Shareholder Yield | -24.92% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Clal Biotechnology Industries has an Altman Z-Score of -16.38. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -16.38 |
| Piotroski F-Score | n/a |